Silexion Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: SLXNW · Form: 8-K · Filed: Jul 14, 2025 · CIK: 2022416

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, company-update

TL;DR

Silexion Therapeutics is holding a shareholder vote on July 14, 2025.

AI Summary

Silexion Therapeutics Corp. filed an 8-K on July 14, 2025, reporting on a submission of matters to a vote of security holders. The company, formerly known as Biomotion Sciences until May 6, 2024, is incorporated in the Cayman Islands and operates in the biological products sector. Its principal executive offices are located in Ramat-Gan, Israel.

Why It Matters

This filing indicates a significant corporate event where Silexion Therapeutics is seeking approval from its security holders, which could impact the company's future direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an event that inherently carries significant financial risk on its own.

Key Players & Entities

FAQ

What specific matters are being submitted to a vote of security holders?

The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals in the provided text.

When was Silexion Therapeutics Corp. formerly known as Biomotion Sciences?

The company was formerly known as Biomotion Sciences until May 6, 2024.

Where are Silexion Therapeutics Corp.'s principal executive offices located?

The principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.

What is the Commission File Number for Silexion Therapeutics Corp?

The Commission File Number is 001-42253.

What is the SIC code for Silexion Therapeutics Corp?

The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 14, 2025 regarding Silexion Therapeutics Corp (SLXNW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing